To demonstrate that our transgenic construct was able to constitutively activate PI3-kinase pathway, we transient transfected myr-PIK3CA, wt-PIK3CA and control vectors to ovarian cancer cell line 2008. This evidence concerns the gene PIK3CA and ovarian carcinoma.